New insights into the role of anabolic interventions in dialysis patients with protein energy wasting

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 6, 2009, Pages 469-475

  Dong, Jie ^a   Alp Ikizler, T ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Anabolic agents; Dialysis; Exercise; Nutritional supplementation; Protein energy wasting

Indexed keywords

ANABOLIC AGENT; ANDROGEN; BIM 28125; BIM 28131; GHRELIN; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; MUSCLE PROTEIN; NANDROLONE DECANOATE; PLACEBO; TESTOSTERONE; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECONOMIC ASPECT; EXERCISE; HEMODIALYSIS PATIENT; HIRSUTISM; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LOW DRUG DOSE; METABOLIC DISORDER; MORBIDITY; MORTALITY; MUSCLE MASS; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL ASSESSMENT; PARENTERAL NUTRITION; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEFICIENCY; PROTEIN ENERGY WASTING; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERA; VOICE CHANGE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMICS; ENTERIC FEEDING; HOSPITAL COST; MULTIMODALITY CANCER THERAPY; PROTEIN CALORIE MALNUTRITION; RENAL REPLACEMENT THERAPY; RESISTANCE TRAINING;

ANABOLIC AGENTS; COMBINED MODALITY THERAPY; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; ENTERAL NUTRITION; HOSPITAL COSTS; HUMANS; PARENTERAL NUTRITION; PROTEIN-ENERGY MALNUTRITION; RENAL DIALYSIS; RESISTANCE TRAINING; TREATMENT OUTCOME;

EID: 73349091583     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328331489d     Document Type: Review

References (69)

1. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50:343-357. This is an important review coauthored by an expert panel convened by the International Society of Renal Nutrition and Metabolism (ISRNM) to advance a unifying and practical terminology for the PEW syndrome that occurs in many patients with CKD or acute kidney injury. The systematically defined nomenclature and diagnostic criteria will help to clarify thinking and communication, enhance the effectiveness of patient care, and promote more incisive research in this field.
2. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391-398. (Pubitemid 351186278)
3. Lim VS, Ikizler TA, Raj DS, Flanigan MJ. Does hemodialysis increase protein breakdown? Dissociation between whole-body amino acid turnover and regional muscle kinetics. J Am Soc Nephrol 2005; 16:862-868.
4. Ikizler TA, Pupim LB, Brouillette JR, et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002; 282:E107-E116.
5. Ikizler TA, Greene JH, Yenicesu M, et al. Nitrogen balance in hospitalized chronic hemodialysis patients. Kidney Int Suppl 1996; 57:S53-S56. (Pubitemid 26418471)
6. Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA. Intradialytlc oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 2006; 1 7:3149-3157.
7. Caglar K, Fedje L, Dimmitt R, et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 2002; 62:1054-1059. (Pubitemid 35316737)
8. Eustace JA, Coresh J, Kutchey C, et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 2000; 57:2527-2538. (Pubitemid 30340751)
9. Sharma M, Rao M, Jacob S, Jacob CK. A controlled trial of intermittent enteral nutrient supplementation in maintenance hemodialysis patients. J Ren Nutr 2002; 12:229-237.
10. Cano N, Labastie-Coeyrehourq J, Lacombe P, et al. Perdialytic parenteral nutrition with lipids and amino acids in malnourished hemodialysis patients. Am J Clin Nutr 1990; 52:726-730. (Pubitemid 20312666)
11. Navarro JF, Mora C, Leon C, et al. Amino acid losses during hemodialysis with polyacrylonitrile membranes: effect of intradialytic amino acid supplementation on plasma amino acid concentrations and nutritional variables In non-diabetic patients. Am J Clin Nutr 2000; 71:765-773. (Pubitemid 30118570)
12. Cano NJ, Saingra Y, Dupuy AM, et al. Intradialytic parenteral nutrition: comparison of olive oil versus soybean oil-based lipid emulsions. Br J Nutr 2006; 95:152-159. (Pubitemid 43250722)
13. Mortelmans AK, Duym P, Vandenbroucke J, et al. Intradialytic parenteral nutrition in malnourished hemodialysis patients: a prospective long-term study. JPEN J Parenter Enteral Nutr 1999; 23:90-95. (Pubitemid 29115426)
14. Kalantar-Zadeh K, Braglia A, Chow J, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr 2005; 15:318-331. (Pubitemid 40917292)
15. Stratton RJ, Bircher G, Fouque D, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2005; 46:387-405. (Pubitemid 41208174)
16. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18:2583-2591. This is the first study to compare the impact of two types of IDPN differing by their fatty acid content on nutritional parameters, plasma lipids and markers of oxidative stress, inflammation and immune status. The results are indicative of comparable effects between two groups. This study is one of the largest randomized clinical trials on nutritional interventions in chronic hemodialysis patients.
17. Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001 ; 37 (1 Suppl.2):S66S70.
18. Teixido-Planas J, Ortiz A, Coronel F, et al. Oral protein-energy supplements in peritoneal dialysis: a multicenter study. Perit Dial Int 2005; 25:163-172. (Pubitemid 40484728)
19. Tjiong HL, van den Berg JW, Wattimena JL, et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
20. Tjiong HL, Rietveld T, Wattimena JL, et al. Peritoneal dialysis with solutions containing amino acids plus glucose promotes protein synthesis during oral feeding. Clin J Am Soc Nephrol 2007; 2:74-80.
21. Asola M, Virtanen K, Nagren K, et al. Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle. Kidney Int Suppl 2008; (108):S131-S136. This study used positron emission tomography that reflects metabolism and especially amino acid transport and showed that amino acid-containing peritoneal dialysis solution plus glucose-based peritoneal dialysis solutions administered for 6 weeks is associated with a significant increase in skeletal muscle amino acid uptake both in the fasting state and during insulin stimulation as compared with glucose-based peritoneal dialysis solutions only.
22. Li FK, Chan LY, Woo JC, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42:173-183.
23. Park MS, Choi SR, Song YS et al. New insight of amino acid-based dialysis solutions. Kidney Int Suppl 2006; (103):S110-S114. (Pubitemid 44684785)
24. Johansen KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol 2007; 18:1845-1854. (Pubitemid 46870321)
25. Singh MA. Exercise comes of age: rationale and recommendations for a geriatric exercise prescription. J Gerontol A Biol Sci Med Sci 2002; 57:M262-M282.
26. Cheema BS, Smith BC, Singh MA. A rationale for intradialytic exercise training as standard clinical practice in ESRD. Am J Kidney Dis 2005; 45:912-916.
27. Cheema BS, Singh MA. Exercise training in patients receiving maintenance hemodialysis: a systematic review of clinical trials. Am J Nephrol 2005; 25:352-364.
28. Johansen KL, Chertow GM, Ng AV, et al. Physical activity levels In patients on hemodialysis and healthy sedentary controls. Kidney Int 2000; 57:25642570.
29. Johansen KL, Shubert T, Doyle J, et al. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. Kidney Int 2003; 63:291-297. (Pubitemid 35463933)
30. O'Hare AM, Tawney K, Bacchetti P, Johansen KL. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 2003; 41:447-454. (Pubitemid 36152466)
31. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366-2372. (Pubitemid 37069205)
32. Desmeules S, Levesque R, Jaussent I, et al. Creatinine index and lean body mass are excellent predictors of long-term survival In haemodiafiltration patients. Nephrol Dial Transplant 2004; 19:1182-1189. (Pubitemid 38628139)
33. Stack AG, Molony DA, Rives T, et al. Association of physical activity with mortality in the US dialysis population. Am J Kidney Dis 2005; 45:690-701. (Pubitemid 40460757)
34. Painter P, Johansen KL Improving physical functioning: time to be a part of routine care. Am J Kidney Dis 2006; 48:167-170. (Pubitemid 43912962)
35. Koopman R, van Loon LJ. Aging, exercise, and muscle protein metabolism. J Appl Physiol 2009; 106:2040-2048.
36. Johansen KL, Painter PL, Sakkas GK, et al. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J Am Soc Nephrol 2006; 17:2307-2314.
37. Cheema B, Abas H, Smith B, et al. Progressive exercise for anabolism in kidney disease (PEAK): a randomized, controlled trial of resistance training during hemodialysis. J Am Soc Nephrol 2007; 18:1594-1601. (Pubitemid 46729199)
38. Cheema B, Abas H, Smith B, et al. Randomized controlled trial of intradialytic resistance training to target muscle wasting in ESRD: the Progressive Exercise for Anabolism in Kidney Disease (PEAK) study. Am J Kidney Dis 2007; 50:574-584. (Pubitemid 47444459)
39. Kopple JD, Wang H, Casaburi R, et al. Exercise in maintenance hemodialysis patients induces transcriptional changes In genes favoring anabolic muscle. J Am Soc Nephrol 2007; 18:2975-2986. (Pubitemid 350064083)
40. Mehls O, Tonshoff B, Blum WF, et al. Growth hormone and insulin-like growth factor I in chronic renal failure: pathophysiology and rationale for growth hormone treatment. Acta Paediatr Scand Suppl 1990; 370:28-34; discussion 35. (Pubitemid 20342266)
41. Iglesias P, Diez JJ, Fernandez-Reyes MJ, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32:454-463. (Pubitemid 28411219)
42. Johannsson G, Bengtsson BA, Ahlmen J. Double-blind, placebo-controlled study of growth hormone treatment In elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999;33:709-717. (Pubitemid 29159937)
43. Hansen TB, Gram J, Jensen PB, et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53:99-107.
44. Kotzmann H, Yilmaz N, Lercher P, et al. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int 2001 ; 60:15781585. (Pubitemid 32960055)
45. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18:2161-2171. This is the largest prospective, randomized study in adult hemodialysis patients to show a significant beneficial effect of human growth hormone (hGH) on LBM. A dose-dependent reduction in body fat mass in hGH-treated patients was observed. hGH treatment had a favorable impact on cardiovascular risk markers such as serum transferrin, serum HDL and plasma homocysteine.
46. Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1741-1751. This study was designed to assess the effects of GH on mortality In a larger group of MHD patients but was terminated due to slow recruitment. No increased risk with GH was observed. The early termination of this study attests to the complicated nature of the CHD patients and complexity of executing RCTs in this patient population.
47. Albaaj F, Sivalingham M, Haynes P, et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J 2006; 82:693-696. (Pubitemid 44786879)
48. de Vries CP, Gooren LJ, Oe PL. Haemodialysis and testicular function, Int J Androl 1984; 7:97-103.
49. Doumouchtsis KK, Kostakis Al, Doumouchtsls SK, et al. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL Hemodlal Int 2008; 12:100-107.
50. Karakitsos D, Patrianakos AP, De Groot E, et al. Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 2006; 26:536-543. (Pubitemid 46143875)
51. Carrero JJ, Qureshi AR, Parini P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20:613620. This is the first report to show that testosterone concentrations are inversely related to mortality due to both cardiovascular disease (CVD) and all causes in male hemodialysis patients. This association was attenuated after adjustment for screatinlne. Strong inverse independent correlations were observed between testosterone and various inflammatory markers.
52. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670-2677. (Pubitemid 32269134)
53. Svartberg J, Aasebo U, Hjalmarsen A, et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004; 98:906-913. (Pubitemid 39069342)
54. Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002; 2:692-699. (Pubitemid 35265065)
55. Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58:38-46. (Pubitemid 34752992)
56. Dombros NV, Digenis GE, Soliman G, Oreopoulos DG. Anabolic steroids in the treatment of malnourished CAPD patients: a retrospective study. Perit Dial Int 1994; 14:344-347. (Pubitemid 24338561)
57. Gascon A, Belvis JJ, Berisa F, et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9:67-72. (Pubitemid 29438143)
58. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275-1281. (Pubitemid 29174478)
59. Macdonald JH, Marcora SM, Jibani MM, et al. Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dosefinding study. Nephron Clin Pract 2007; 106:c 125-c 135.
60. Kamiji MM, Inui A. The role of ghrelin and ghrelin analogues in wasting disease. Curr Opin Clin Nutr Metab Care 2008; 11 443-451.
61. Granado M, Martin Al, Lopez-Menduina M, et al. GH-releasIng peptide-2 administration prevents liver inflammatory response In endotoxemia. Am J Physiol Endocrinol Metab 2008; 294:E131-E141. This comprehensive review highlights recent developments in research with ghrelin in wasting conditions such as cancer, diabetes mellitus, malabsorptive diseases, chronic obstructive pulmonary disease, anorexia nervosa, renal failure, liver failure and chronic heart failure.
62. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008, 149:601-611.
63. Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 2008; 149:827-835. (Pubitemid 351159354)
64. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005; 16:2111-2118. (Pubitemid 41716442)
65. Biolo G, Tipton KD, Klein S, Wolfe RR. An abundant supply of amino acids enhances the metabolic effect of exercise on muscle protein. Am J Physiol 1997; 273 (1 Pt 1 ):E122-E129. (Pubitemid 27342763)
66. Gautsch TA, Anthony JC, Kimball SR, et al. Availability of elF4E regulates skeletal muscle protein synthesis during recovery from exercise. Am J Physiol 1998; 274 (2 Pt 1):C406-C414. (Pubitemid 28140784)
67. Majchrzak KM, Pupim LB, Flakoll PJ, Ikizler TA. Resistance exercise augments the acute anabolic effects of intradialytic oral nutritional supplementation. Nephrol Dial Transplant 2008; 23:1362-1369. This metabolic study shows the additive beneficial effect of resistance exercise on protein accretion obtained by nutritional supplementation alone and provides a rationale for future long-term studies using this combined nutritional intervention strategy.
68. Pupim LB, Flakoll PJ, Yu C, Ikizler TA. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 2005; 82:1235-1243. (Pubitemid 43779722)
69. Lacson E Jr, Ikizler TA, Lazarus JM, et al. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr 2007; 17:363-371.